Insider Trading Alert - DVA, DATA And KERX Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Sept. 10, 2014, 87 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $485.14 to $187,394,342.10.

Highlighted Stocks Traded by Insiders:

DaVita HealthCare Partners (DVA) - FREE Research Report

Rivera Kim M, who is Chief Legal Officer at DaVita HealthCare Partners, sold 1,111 shares at $74.25 on Sept. 10, 2014. Following this transaction, the Chief Legal Officer owned 2,921 shares meaning that the stake was reduced by 27.55% with the 1,111-share transaction.

The shares most recently traded at $74.00, down $0.25, or 0.34% since the insider transaction. Historical insider transactions for DaVita HealthCare Partners go as follows:

  • 4-Week # shares sold: 2,500
  • 12-Week # shares sold: 2,803
  • 24-Week # shares sold: 55,273

The average volume for DaVita HealthCare Partners has been 862,700 shares per day over the past 30 days. DaVita HealthCare Partners has a market cap of $16.0 billion and is part of the health care sector and health services industry. Shares are up 17.11% year-to-date as of the close of trading on Wednesday.

DaVita HealthCare Partners Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease. It operates kidney dialysis centers and provides related lab services primarily in outpatient dialysis centers and in contracted hospitals. The company has a P/E ratio of 23.5. Currently, there are 7 analysts who rate DaVita HealthCare Partners a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DVA - FREE

TheStreet Quant Ratings rates DaVita HealthCare Partners as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full DaVita HealthCare Partners Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Tableau Software (DATA) - FREE Research Report

Conder Keenan Michael, who is VP, GC & Secretary at Tableau Software, sold 7,500 shares at $70.00 on Sept. 10, 2014. Following this transaction, the VP, GC & Secretary owned 26,920 shares meaning that the stake was reduced by 21.79% with the 7,500-share transaction.

The shares most recently traded at $73.30, up $3.30, or 4.5% since the insider transaction. Historical insider transactions for Tableau Software go as follows:

  • 4-Week # shares sold: 37,047
  • 12-Week # shares sold: 39,047
  • 24-Week # shares sold: 148,047

The average volume for Tableau Software has been 1.3 million shares per day over the past 30 days. Tableau Software has a market cap of $2.9 billion and is part of the technology sector and computer software & services industry. Shares are up 5.69% year-to-date as of the close of trading on Wednesday.

Tableau Software, Inc. provides various business analytics software products in the United States, Canada, and internationally. The company has a P/E ratio of 464.9. Currently, there are 7 analysts who rate Tableau Software a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DATA - FREE

TheStreet Quant Ratings rates Tableau Software as a sell. The company's weaknesses can be seen in multiple areas, such as its generally disappointing historical performance in the stock itself, feeble growth in its earnings per share and unimpressive growth in net income. Get the full Tableau Software Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Keryx Biopharmaceuticals (KERX) - FREE Research Report

Oliviero James F III, who is Chief Financial Officer at Keryx Biopharmaceuticals, sold 144,237 shares at $15.88 on Sept. 10, 2014. Following this transaction, the Chief Financial Officer owned 156,039 shares meaning that the stake was reduced by 48.03% with the 144,237-share transaction.

The shares most recently traded at $14.27, down $1.61, or 11.28% since the insider transaction. Historical insider transactions for Keryx Biopharmaceuticals go as follows:

  • 4-Week # shares sold: 3,842
  • 12-Week # shares sold: 3,842
  • 24-Week # shares sold: 7,745

The average volume for Keryx Biopharmaceuticals has been 2.1 million shares per day over the past 30 days. Keryx Biopharmaceuticals has a market cap of $1.3 billion and is part of the health care sector and drugs industry. Shares are up 11.2% year-to-date as of the close of trading on Wednesday.

Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease in the United States. Currently, there are 8 analysts who rate Keryx Biopharmaceuticals a buy, 1 analyst rates it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on KERX - FREE

TheStreet Quant Ratings rates Keryx Biopharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and poor profit margins. Get the full Keryx Biopharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Legal Weed Sales in California Are Off to a Less Than Smokin' Start

Legal Weed Sales in California Are Off to a Less Than Smokin' Start

Stocks Waver Amid Progress on U.S.-China Trade; Dow Slips

Stocks Waver Amid Progress on U.S.-China Trade; Dow Slips

Owner of Moviepass Sees Stock Plummet

Owner of Moviepass Sees Stock Plummet

Ford, GM Gain as China Slashes Auto Import Tariffs

Ford, GM Gain as China Slashes Auto Import Tariffs

U.S. Crude Oil Hits Fresh 3-Year Highs as Gasoline Heads to $3 a Gallon

U.S. Crude Oil Hits Fresh 3-Year Highs as Gasoline Heads to $3 a Gallon